Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Torsin-1A is an AAA+ ATPase chaperone protein predominantly found in the endoplasmic reticulum and nuclear envelope, encoded by the TOR1A gene on human chromosome 9[1][2][3][4][5]. It is involved in protein folding and processing, quality control of misfolded proteins, regulation of synaptic vesicle trafficking, and maintenance of nuclear envelope integrity, particularly in neurons[2][3][5]. Mutations, most notably the ΔGAG deletion, in TOR1A cause early-onset isolated dystonia (DYT1), a neurological disorder characterized by involuntary muscle contractions and abnormal movements[1][2][3]. Torsin-1A is especially important for neuronal function in dopamine-producing regions such as the substantia nigra[3]. While central to inherited dystonias, interactions with drugs and biomarker usage remain unclear. The gene product is a potential therapeutic target for neurogenetic movement disorders, but disruption of its activity risks exacerbating neurodegeneration or movement abnormalities[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Torsin-1A (TOR1A).